#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Campylobacteriosis at the Department of Infectious Diseases of the University Hospital Brno in 2011–2013: a retrospective study


Authors: P. Polák 1,2;  M. Vrba 3;  Z. Bortlíček 4;  J. Juránková 3,5;  M. Freibergerová 1;  P. Husa 1,2;  J. Kamelander 6;  M. Dastych 1,7
Authors place of work: Lékařská fakulta Masarykovy univerzity Brno 1;  Klinika infekčních chorob, Fakultní nemocnice Brno 2;  Oddělení klinické mikrobiologie, Fakultní nemocnice Brno 3;  Institut biostatistiky a analýz, Lékařská fakulta Masarykovy univerzity Brno 4;  Katedra laboratorních metod, Lékařská fakulta Masarykovy univerzity Brno 5;  Oddělení klinické hematologie, Fakultní nemocnice Brno 6;  Oddělení klinické biochemie, Fakultní nemocnice Brno 7
Published in the journal: Epidemiol. Mikrobiol. Imunol. 64, 2015, č. 3, s. 153-159
Category: Original Papers

Summary

Objective:
To provide basic clinical, laboratory, and microbiological characteristics of adult patients with campylobacteriosis admitted to the Department of Infectious Diseases University Hospital Brno (UHB), in 2011–2013.

Materials and methods:
A retrospective analysis of clinical and laboratory parameters of 160 patients hospitalized with campylobacteriosis at the Department of Infectious Diseases, UHB from 1 January 2011 to 31 December 2013.

Results:
There was no lethality or bacteremia reported in the study group of 160 adult patients (n = 160) with campylobacteriosis. A more severe form of the disease with signs of systemic inflammatory response syndrome (SIRS) occurred in 24 patients, i.e. 15% of the study population. Transient mild to moderate leukocytopenia and thrombocytopenia were seen in 16 (10.0%) and 24 patients (15.0%), respectively, and seven patients (4.4%) had bicytopenia. The following factors correlated statistically significantly with the intestinal form of the disease and SIRS: age under 70 years (p = 0.037), absence of arterial hypertension (p = 0.044), immunosuppressive treatment (p = 0.008), leukocyte count in the peripheral blood over 12.0 × 109/l (p = 0.023), and body temperature over 38.0 °C (p < 0.001). Antibiotic treatment was used in 96.3% of patients with the intestinal form and in 100.0% of patients with SIRS. The average duration of antibiotic treatment was 8.8 and 9.3 days, respectively. Postantibiotic colitis due to Clostridium difficile occurred in seven patients (4.4%). There were no organ or autoimmune complications observed.

Conclusions:
Campylobacteriosis with SIRS occurs preferentially in persons under 70 years of age. Empirical antibiotic treatment is used too frequently without being adequately deescalated.

Keywords:
campylobacteriosis – invasive disease – antibiotic resistance


Zdroje

1. Ajene AN, Fischer Walker CL, Black RE. Enteric pathogens and reactive arthritis: a systematic review of Campylobacter, salmonella and Shigella-associated reactive arthritis. J Health Popul Nutr, 2013;31(3):299–307.

2. Ariganello P, Angelino G, Scarselli A, et al. Relapsing Campylobacter jejuni systemic infections in a child with X-linked agammaglobulinemia. Case Rep Pediatr, 2013;2013:735108.

3. Bardoň J, Ondrušková J, Oslíková M, Vyroubalová Š. Zoonotický potenciál syrového kravského mléka v ČR. Klin mikrobiol inf lék, 2012;18(2):32–37.

4. Bardoň J, Kolář M, Čekanová L, et al. Prevalence of Campylobacter jejuni and its Resistance to Antibiotics in Poultry in the Czech Republic. Zoonoses and Public Health, 2009;56:111–116.

5. Bardoň J., Kolář M, Karpíšková R, et al. Prevalence of thermotolerant Campylobacter spp. in broilers at retail in the Czech Republic and their antibiotic resistance. Food Control, 2011;22:328–332.

6. Ben-Shimol S, Carmi A, Greenberg D. Demographic and clinical characteristics of Campylobacter bacteremia in children with and without predisposing factors. Pediatr Infect Dis J, 2013;32(11):e414–418. doi: 10.1097/INF.0b013e31829baae0.

7. Bessède E, Lehours P, Labadi L, et al. Comparison of characteristics of patients infected by Campylobacter jejuni, Campylobacter coli, and Campylobacter fetus. J Clin Microbiol, 2014;52(1):328–330.

8. Brophy S, Jones KH, Rahman M, et al. Incidence of Campylobacter and Salmonella infections following first prescription for PPI: A cohort study using routine data. Am J Gastroenterol, 2013;108:1094–1100.

9. Epps SV, Harvey RB, Hume ME, et al. Foodborne campylobacter: infections, metabolism, pathogenesis and reservoirs. Int J Environ Res Public Health, 2013;10(12):6292–6304.

10. Fernández-Cruz A, Muñoz P, Mohedano R, et al. Campylobacter bacteremia: clinical characteristics, incidence, and outcome over 23 years. Medicine (Baltimore), 2010;89(5):319–330.

11. Fischer S, Kittler S, Klein G, et al. Impact of a single phage and a phage cocktail application in broilers on reduction of Campylobacter jejuni and development of resistance. PLoS One, 2013;8(10):e78543.

12. Garg AX, Moist L, Matsell D, et al. Risk of hypertension and reduced kidney function after acute gastroenteritis from bacteria-contaminated drinking water. CMAJ, 2005;73(3):261–268.

13. Gazaigne L, Legrand P, Renaud B, et al. Campylobacter fetus bloodstream infection: risk factors and clinical features. Eur J Clin Microbiol Infect Dis, 2008;27(3):185–189.

14. Horn BJ, Lake RJ. Incubation period for campylobacteriosis and its importance in the estimation of incidence related to travel. Euro Surveill, 2013;18(40).

15. Hugunin KM, Fry C, Shuster K, et al. Effects of tramadol and buprenorphine on select immunologic factors in a cecal ligation and puncture model. Shock, 2010;34(3):250–260.

16. Iovine NM. Resistance mechanisms in Campylobacter jejuni. Virulence, 2013;4(3):230–240.

17. Iwata T, Chiku K, Amano K, al. Effects of lipooligosaccharide inner core truncation on bile resistance and chick colonization by Campylobacter jejuni. PLoS One, 2013;8(2):e56900.

18. Janež N, Loc-Carrillo C. Use of phages to control Campylobacter spp. J Microbiol Methods, 2013;95(1):68–75.

19. Kahlich R, Paleček A. Kampylobakterioza v ČSSR. Informační zpravodaj. Vojenská lékařská akademie JEP v Hradci Králové. 1983;24(1):15–33.

20. Kopecký O, Horáček J, Černá Pařízková R, et al. Campylobacter sepsis with multiple organ failure in IgG subclass deficiency. Folia microbiologica, 2006;51(6):604–608.

21. Kotalová R. Léčba akutních gastroenteritid. Postgrad Med, 2010;12(suppl. 2):6–15.

22. Latová Z, Nezval J, Sedláčková D, et al. Vývoj infekčních střevních onemocnění u pacientů Kliniky infekčních chorob v Brně v letech 1970–1975. Čas lék čes, 1978;117(10):295–299.

23. Lexová P, Beneš Č, Částková J, et al. Výskyt infekčních onemocnění přenášených potravinami a vodou v ČR – rok 2012 a trendy nemocnosti. Zprávy Centra epidemiologie a mikrobiologie, 2013;22(7):233–239.

24. Malik-Kale P, Parker CT, Konkel ME. Culture of Campylobacter jejuni with sodium deoxycholate induces virulence gene expression. J Bacteriol, 2008;190(7):2286–2297.

25. Nielsen H, Hansen KK, Gradel KO, et al. Bacteraemia as a result of Campylobacter species: a population-based study of epidemiology and clinical risk factors. Clin Microbiol Infect, 2010;16(1):57–61.

26. Osterberg J, Ljungdahl M, Haglund U. Influence of cyclooxygenase inhibitors on gut immune cell distribution and apoptosis rate in experimental sepsis. Shock, 2006;25(2):147–154.

27. Piesecká Lˇ, Votrubová A, Líšková A, et al. Kampylobakterová infekcia komplikovaná oligoartritídou a Raynaudovým fenoménom. Postgrad med, 2010;12(8):915–917.

28. Poracká Ľ, Schréter I. Niektoré klinické hľadiská pri vybraných bakteriálnych črevných nákazách. Časť 2. K priebehu salmonelózy, šigelózy, kampylobakteriózy a yerziniózy u dospelých ľudí. Slov lek, 1998;8(3),15–18.

29. Randall LP, Ridley AM, Cooles SW, et al. Prevalence of multiple antibiotic resistance in 443 Campylobacter spp. isolated from humans and animals. J Antimicrob Chemoth, 2003;52:507–510.

30. Reimer C. Safety of long-term PPI therapy. Best Pract Res Clin Gastroenterol, 2013;27(3):443–454.

31. Roy S, Ninkovic J, Banerjee S, et al. Opioid drug abuse and modulation of immune function: consequences in the susceptibility to opportunistic infections. J Neuroimmune Pharmacol, 2011;4:442–465.

32. Sharma M. Lytic bacteriophages: Potential interventions against enteric bacterial pathogens on produce. Bacteriophage, 2013;1(3):2:e25518.

33. Schattner A. Campylobacter jejuni and cytopenias. Am J Med, 2013;126(11):1020–1021.

34. Shen Z, Pu X-Y, Zhang Q. Salicylate functions as an efflux pump inducer and promotes the emergence of fluoroquinolone-resistant Campylobacter jejuni mutants. Appl Environ Microbiol, 2011;77(20):7128–7133.

35. Smith GS, Blaser MJ. Fatalities associated with Campylobacter jejuni infections. JAMA, 1985;253(19):2873–2875.

36. Táborská J, Kobesová A. Kampylobakteriózy u hospitalizovaných dětí do tří let věku. Prakt lék, 1997;77(10):485–488.

37. van der Veen EL, Schilder AG, Timmers TK, et al. Effect of long-term trimethoprim/sulfamethoxazole treatment on resistance and integron prevalence in the intestinal flora: a randomized, double-blind, placebo-controlled trial in children. J Antimicrob Chemother, 2009;63(5):1011–1016.

38. Virtová S, Táborská J, Valchová M, et al. Salmonelózy a kampylobakteriózy u dospělých. Prakt lék, 1998;78(6):295–298.

39. Wagenaar JA, French NP, Havelaar AH. Preventing Campylobacter at the source: why is it so difficult? Clin Infect Dis, 2013;57(11):1600–1606.

40. Wieczorek K, Osek J. Antimicrobial resistance mechanisms among Campylobacter. Biomed Res Int, 2013;2013:340605.

41. Zautner AE, Johann C, Strubel A, et al. Seroprevalence of campylobacteriosis and relevant post-infectious sequelae. Eur J Clin Microbiol Infect Dis, 2014;33(6):1019–1027.

42. Zhangqi S, Xiao-Ying P, Qijing Z. Salicylate functions as an efflux pump inducer and promotes the emergence of fluoroquinolone-resistant Campylobacter jejuni mutants. Appl Environ Microbiol, 2011;77(20):7128–7133.

Štítky
Hygiene and epidemiology Medical virology Clinical microbiology
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#